Publicaciones en las que colabora con J. Egea (54)

2023

  1. Melatonin as Modulator for Sulfur and Nitrogen Mustard-Induced Inflammation, Oxidative Stress and DNA Damage: Molecular Therapeutics

    Antioxidants, Vol. 12, Núm. 2

  2. m-Terphenylamines, Acting as Selective COX-1 Inhibitors, Block Microglia Inflammatory Response and Exert Neuroprotective Activity

    Molecules, Vol. 28, Núm. 14

2022

  1. Synthesis and Pharmacological Evaluation of New N-Sulfonylureas as NLRP3 Inflammasome Inhibitors: Identification of a Hit Compound to Treat Gout

    Journal of Medicinal Chemistry, Vol. 65, Núm. 8, pp. 6250-6260

2021

  1. Analogues of cannabinoids as multitarget drugs in the treatment of Alzheimer's disease

    European Journal of Pharmacology, Vol. 895

  2. Privileged quinolylnitrones for the combined therapy of ischemic stroke and alzheimer’s disease

    Pharmaceuticals, Vol. 14, Núm. 9

  3. Toxicology of Blister Agents: Is Melatonin a Potential Therapeutic Option?

    DISEASES, Vol. 9, Núm. 2

2020

  1. In Vitro and in Silico ADME-Tox Profiling and Safety Significance of Multifunctional Monoamine Oxidase Inhibitors Targeting Neurodegenerative Diseases

    ACS Chemical Neuroscience, Vol. 11, Núm. 22, pp. 3793-3801

  2. Na+ controls hypoxic signalling by the mitochondrial respiratory chain

    Nature, Vol. 586, Núm. 7828, pp. 287-291

2019

  1. New Dual Small Molecules for Alzheimer's Disease Therapy Combining Histamine H3 Receptor (H3R) Antagonism and Calcium Channels Blockade with Additional Cholinesterase Inhibition

    Journal of Medicinal Chemistry, Vol. 62, Núm. 24, pp. 11416-11422

  2. Nrf2 plays a protective role against intravascular hemolysis-mediated acute kidney injury

    Frontiers in Pharmacology, Vol. 10

  3. Quinoxalinetacrine QT78, a cholinesterase inhibitor as a potential ligand for Alzheimer’s disease therapy

    Molecules, Vol. 24, Núm. 8

2018

  1. Analysis of gene expression profiles of CR80, a neuroprotective 1,8-Naphthyridine

    Future Medicinal Chemistry, Vol. 10, Núm. 11, pp. 1289-1300

  2. Corrigendum to “European contribution to the study of ROS: A summary of the findings and prospects for the future from the COST action BM1203 (EU-ROS)” (Redox Biol. (2017) 13 (94–162)(S2213231717303373)(10.1016/j.redox.2017.05.007))

    Redox Biology

  3. Folic Acid Protects Against Glutamate-Induced Excitotoxicity in Hippocampal Slices Through a Mechanism that Implicates Inhibition of GSK-3β and iNOS

    Molecular Neurobiology, Vol. 55, Núm. 2, pp. 1580-1589

2017

  1. ConBr, A Lectin Purified from the Seeds of Canavalia brasiliensis, Protects Against Ischemia in Organotypic Culture of Rat Hippocampus: Potential Implication of Voltage-Gated Calcium Channels

    Neurochemical Research, Vol. 42, Núm. 2, pp. 347-359

  2. Enzymatic and solid-phase synthesis of new donepezil-based L- and D-glutamic acid derivatives and their pharmacological evaluation in models related to Alzheimer's disease and cerebral ischemia

    European Journal of Medicinal Chemistry, Vol. 130, pp. 60-72

  3. European contribution to the study of ROS: A summary of the findings and prospects for the future from the COST action BM1203 (EU-ROS)

    Redox Biology, Vol. 13, pp. 94-162

  4. Ischemic brain injury: New insights on the protective role of melatonin

    Free Radical Biology and Medicine, Vol. 104, pp. 32-53

  5. Melatonin as a versatile molecule to design novel multitarget hybrids against neurodegeneration

    Future Medicinal Chemistry, Vol. 9, Núm. 8, pp. 765-780

  6. Mitochondrial complex I deactivation is related to superoxide production in acute hypoxia

    Redox Biology, Vol. 12, pp. 1040-1051